Kevin Li

Kevin Li, Ph.D., is a Senior Advisor in Therapeutic Gene Editing at Eli Lilly and Company, where they currently focus on advancing gene editing technologies. With over 10 years of experience in gene editing and gene therapy, they previously contributed to the Liver Research and Development team at Spark Therapeutics, Inc. Kevin earned a Ph.D. in Bioengineering from Rice University, where their thesis centered on gene editing, and achieved a B.S. in Biomedical Engineering from the Georgia Institute of Technology, graduating summa cum laude. Their expertise includes molecular biology and various gene editing technologies, along with managing collaborative projects across multiple sectors.